The oncogene v-jun was originally identified as the transforming gene of avian sarcoma virus 17, whose gag-jun fusion protein (p655-jun) induces fibrosarcomas in chickens and is capable of transforming but not immortalizing chicken embryo fibroblasts (1) . Its normal cellular homologue, c-jun, encodes a 39-kDa nuclear phosphoprotein (Jun) which forms complexes with the Fos protein and activates transcription of genes having specific DNA-binding sequences in their promoter/enhancer regions (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . c-jun is expressed in several tissues and its expression, along with that of c-fos, increases after a variety of stimuli, including growth factors. c-jun and c-fos therefore appear to act as immediate early response genes, coupling short-term signals received at the cell membrane to long-term adaptive cellular responses by altering patterns of gene expression (12) (13) (14) .
The role ofJun in transcriptional regulation was discovered when it was found to share amino acid sequence homology with the DNA-binding domain of the yeast transcription factor GCN4 (15) . This homology was sufficient to allow replacement of the DNA-binding domain of GCN4 by the region of similarity in Jun with retention of function as a transcriptional activator (16) . This was followed by the discovery that Jun had amino acid sequence homology and antigenic similarity with the mammalian transcriptional activator protein 1 (AP-1), which was initially identified in HeLa cells (2, 4) . Recent data from several laboratories have demonstrated that AP-1 preparations contain several distinct proteins that, either directly or indirectly via protein complexes, bind to the AP-1 DNA target sequence [TGA(C/ G)TCA], but only one of which represents p39ciun (2, 5, 17, 18) . AP-1/Jun-binding sites have been found in the enhancer/ promoter elements of simian virus 40 (SV40) and of several vertebrate genes, such as human metallothionein IIA or collagenase I (4, 19) . In addition, the transcription of genes which contain an AP-1/Jun binding site in their 5' flanking region is inducible by phorbol ester tumor promoters, such as phorbol 12-tetradecanoate 13-acetate (PTA), and synthetic copies of such binding sites are sufficient to confer PTA-and AP-1/Jun-inducible enhancer activity on heterologous genes (3, 4, 10, 11, 19) . The increase in the DNA-binding activity of AP-1 which has been observed after treatment of cells with PTA has been suggested to result from PTA activation of protein kinase C leading to posttranslational modifications of the AP-1/Jun protein (3, 4) .
Given the findings that c-jun is involved in mediating cellular responses to tumor promoters and growth factors and the transforming activity of v-jun, we investigated if a deregulated expression of the normal c-jun gene can lead to malignant transformation of normal mammalian cells.
MATERIALS AND METHODS
Plasmid Vectors. The mammalian expression vector pVcos-7 containing two tandem Moloney murine leukemia virus long terminal repeats (LTRs) was obtained from S. Goff (Columbia Univ., New York) (20) , and a neomycin resistance gene under the control of an SV40 promoter was inserted downstream from the LTRs to give pVcos-7neo. A 5.6-kilobase (kb) EcoRI fragment containing the entire c-jun gene was isolated from a 10-kb human genomic phage clone, generously provided by P. Vogt (Univ. of Southern California, Los Angeles) (2) , and subcloned in pVcos-7neo in the sense [pJun(genomic sense)] and antisense [pJun(genomic antisense)] orientations and into the pGEM vector (Promega) lacking LTRs [pJun(genomic no LTRs)]. c-jun cDNA clones were isolated from a previously described Agtll library prepared from human small cell lung cancer line NCI-H209 by standard methods (21) , using the 5.6-kb EcoRI c-jun genomic clone as a probe. A 1070-base-pair (bp) cDNA clone was sequenced in M13 in both directions by the dideoxynucleotide method (22) (24) . For transfection studies, plasmid DNAs were prepared by CsCl gradient centrifugation (25) .
Cell Culture and Transfections. Primary cultures of rat embryo cells (RECs) were prepared from 14-day Fisher rat embryos (Charles River Breeding Laboratories) and grown in Dulbecco's modified Eagle's medium (DMEM; GIBCO) supplemented with 10% fetal bovine serum (HyClone) as described (24) . Transfections of the plasmid DNAs were performed in three independent experiments, using calcium phosphate (26) . Equimolar quantities of plasmid DNA (normalized to 10 gg of ras DNA) were used without carrier DNA. After 16-24 hr the precipitate was replaced with fresh growth medium, and 48 hr after transfection each plate of RECs was trypsinized, replated into three or four plates, and fed every 3-4 days. Focus formation was scored at 2 weeks for c-jun and c-myc and at 3 weeks for L-myc. The effect of PTA on transformation of RECs was determined by addition of 100 nM PTA to the DMEM/10% fetal bovine serum culture medium, beginning 2 or 5 days after transfection. Cells were refed with fresh medium containing 100 nM PTA every 4 days.
The immortal line of nonmalignant Fisher rat fibroblasts, Rat-la, a gift from M. Small (Univ. of California, San Francisco) (27, 28) , was maintained in DMEM/10%o fetal bovine serum medium. Rat-la cells were plated at 106 per 100-mm culture dish and 1 day later 5 ml offresh medium was added 4-6 hr before transfection using 10 ug of plasmid DNA. After 16 hr, the precipitate was replaced with fresh medium, and 48 hr after transfection cells from each plate were trypsinized and reseeded into three or four dishes containing culture medium supplemented with antibiotic G418 (GIBCO, 400 ,ug/ml). Independent G418-resistant clones were isolated 10-15 days later.
Assays for Anchorage-Independent Growth and Nude Mouse Tumorigenicity. Control cells, transfected RECs, and Rat-la cells (5 x 104 cells per 60-mm culture dish) were tested for their ability to grow in soft agarose as described (24) . Colony-forming efficiencies were calculated by determining the percentage of cells plated that developed into grossly visible clones in soft agarose after 14 days. Tumorigenicity studies were performed at the Frederick Cancer Research Center (Frederick, MD) by injecting subcutaneously 3 x 106 (RECs) or 5 x 106 (Rat-la) normal or transfected cells into BALB/c nude (nu/nu) mice. The mice were scored for tumor formation (a mass greater than 7 mm) weekly for 4 weeks. In all cases scored positive for tumor formation, progressively growing tumors occurred and the mice were sacrificed when the tumors were 2-2.5 cm in diameter. All animal studies were done under National Institutes of Health approved animal care guideline protocols.
RNA Analysis. RNA was prepared and analyzed as described (24) . Briefly, total RNA (10 ,ug) isolated from individual transfected cell lines was electrophoretically separated on agarose gels, transferred to nitrocellulose filters, and hybridized to 32P-labeled DNA probes. The DNA probes used were (i) for c-jun, a 613-bp EcoRI-Nae I fragment prepared from the 1070-bp EcoRI-EcoRI cDNA clone described above, spanning the 5' portion of the c-jun open reading frame; (it) for c-Ha-ras, a 2.9-kb Sac I fragment from a human c-Ha-ras gene; (iii) for c-myc, a 1.5-kb Cla I-EcoRI fragment of human c-myc. RESULTS c-jun Alone Can Transform Rat-la Cells to Malignancy. The immortal rat fibroblast cell line Rat-la is susceptible to one-step malignant transformation when transfected with oncogenes such as c-myc or N-myc (28) . Since the untransfected, parental cell line Rat-la expresses only low levels of c-jun mRNA, we explored the ability of c-jun to transform these cells as a single gene. After transfection with pJun-(cDNA sense), individual G418-resistant clones were isolated and expanded into cell lines. When analyzed by Northern blot hybridization, 5 of 10 cell lines expressed the transfected c-jun gene (data not shown; mRNA size 3 kb, as in Fig. 2 ).
These cell lines varied up to 7-fold in their human c-jun mRNA expression as determined by densitometric analysis, and 4 of the 5 cell lines were selected for further characterization (Table 1 ). In addition, the lowest expression of human c-jun in these cell lines was approximately 10-to 15-fold higher than the endogenous rat c-jun expression observed in G418-resistant Rat-la cell lines that did not express the transfected c-jun cDNA construct. Morphologic changes were subtle, occurring only in those cell lines with the highest c-jun expression, and consisted of foci of piled-up nonrefractile cells under both subconfluent and confluent conditions.
When tested for anchorage-independent growth and tumorigenicity, Rat-la cell lines expressing human c-jun but not control G418-resistant Rat-la cells expressing the neo gene and no human c-jun formed numerous colonies in soft agarose and gave rise to progressively growing tumors in nude mice (Table 1 ). The transfected cell lines exhibiting the higher levels of c-jun expression also had higher colonyforming efficiencies in soft agarose and gave rise to tumors which grew almost twice as fast as those derived from cell lines expressing lesser amounts of human c-jun, suggesting a correlation between the level of c-jun expression and the degree of transformation. Table 3 ).
(genomic sense) and pJun(genomic antisense)] constructs were transfected alone into cultured primary RECs, and no focus formation suggestive of transformed cells was seen over 4 weeks of observation (Table 2) . Similar results were obtained when pJun(cDNA sense) was cotransfected with a c-myc or an L-myc protooncogene construct (each under the control of retroviral LTRs), each of which was previously shown to cooperate with an activated c-Ha-ras gene in transforming RECs (23, 24) . In addition, when pools of RECs transfected with pJun(cDNA sense) or pJun(genomic sense) were tested for tumorigenicity in nude mice, no tumor formation was observed (Table 2) . c-jun in Cooperation with an Activated c-Ha-ras Gene Induces Transformation of Primary RECs. We next tested the combination of c-jun with an activated c-Ha-ras gene. In three separate experiments, cotransfection of pJun(cDNA sense) or pJun(genomic sense) with the activated c-Ha-ras gene into RECs readily induced focus formation, 20-to 100-fold over any background level seen with the activated c-Ha-ras alone or this ras gene cotransfected with an inactive c-jun construct such as pJun(cDNA antisense) or the pJun-A B (genomic no LTRs), which lacks retroviral enhancer/promoter activity (Table 2) . Focus formation withjun + ras was first visible 7-10 days after transfection, with the transformed cells rapidly covering the plate by week 4. When pools ofcells transfected with pJun(cDNA sense) + ras were injected into nude mice, they readily gave rise to tumors, while injections of ras or pJun(cDNA antisense)/ras-transfected RECs were not tumorigenic (Table 2) . Interestingly, the incidence of focus formation observed with pJun(genomic antisense) + ras was consistently 2-to 4-fold higher than for ras alone. When such foci were isolated (in contrast to the foci seen with ras alone), they were able to form continuously growing cell lines, and pooled cells from pJun(genomic antisense)/ras transfections, when injected into nude mice, were tumorigenic. An explanation for the transforming activity of the pJun(genomic antisense)/ras combination is c-jun sense mRNA transcription off the endogenous human c-jun promoter with enhancer function provided by the Moloney murine leukemia virus LTRs. A similar phenomenon has been reported with use of this expression vector (29) . Properties of RECs Transformed by c-jun Plus ras. We isolated 14 c-jun/ras-induced foci and found that half [4/8 pJun(cDNA sense)/ras, 1/2 pJun(genomic sense)/ras, and 2/4 pJun(genomic antisense)/ras] of the foci gave rise to morphologically transformed, established cell lines (Fig. 1) , while the others failed to grow. The c-jun/ras cell lines were tested for their ability to grow in soft agarose and to form tumors in nude mice. Whereas untransfected RECs were unable to fulfill either ofthese criteria, all of the c-jun/ras cell lines cloned in soft agarose with an efficiency >4% and formed tumors in nude mice within 2 weeks of injection (Table 3) . These lines were passaged regularly for several months without any signs of senescence. In general, the cells exhibited increased refractility, nonadherence to the culture dish, and loss of contact inhibition, tending to pile into several layers. They appeared morphologically more similar to SV40/ras (data not shown) than to c-myc/ras transfectants.
RNA Analysis of c-jun/ras-Transformed RECs. To establish the presence and expression of the transfected genes, we performed Northern blot analysis using total cellular RNA from each of the c-jun/ras-and from one of the c-myc/ ras-induced cell lines (Fig. 2) . These studies (Fig. 2B) revealed that all transformed lines expressed the 1.2-kb c-Ha-ras oncogene mRNA, while in normal RECs (lane 8) no c-Ha-ras expression could be detected. In one case (cell line J-1) a low level of exogenous c-Ha-ras mRNA was found (seen only after longer film exposure than shown in Fig. 2B) . When a c-jun probe was used, marked expression ofan -3-kb c-jun mRNA species was seen in cell lines J-1, J-2, J-5, and J-9 ( Fig. 2A, lanes 1-4) , which had been transfected with the pJun (cDNA sense)/ras combination. This mRNA size is consistent with the calculated size of transcripts initiated and polyadenylylated at the Moloney murine leukemia virus LTRs in pVcos-7neo containing a 1.1-kb c-jun insert (+ z600 bp of LTRs + -200 bp of poly(A) + -1.1-1.2 kb of plasmid sequence containing the EcoRI cloning site between the LTRs), while the smaller mRNAs probably represent truncated mRNA forms. In contrast, the transformed RECs (cell lines 9R-3, 8R-1, and 8R-3) (Fig. 2A, lanes 5-8) transfected with the genomic c-jun constructs [pJun(genomic sense)/ras and pJun(genomic antisense)/ras] showed expression of slightly smaller mRNA species (in the range of 2.6-2.7 kb), the sizes of which are indistinguishable from the endogenous c-jun expression observed in normal RECs and in normal adult rat and human tissues (data not shown). This suggests that the majority of c-jun mRNA in these cells was derived from transcription off the endogenous human jun promoter present on the genomic DNA fragment. Interestingly, while the exogenous c-jun expression in cell lines 9R-3 and 8R-3 clearly exceeds the expression in normal RECs, the expression in cell line 8R-1 is almost identical to the endogenous c-jun mRNA expression by untransfected RECs. Since the level of endogenous rat c-jun mRNA expression may vary among RECs transformed with other oncogenes (compare cell line S3, transformed with SV40/ras, and C4, transformed with c-myc/ras in Fig. 2A) , the transformed phenotype of cell line 8R-1 probably results from the cooperation of ras with LTR-controlled deregulated expression ofexogenous c-jun in these cells. Finally, a Northern blot analysis using a c-myc probe (Fig. 2C) showed a high level of c-myc mRNA in cell line C4, which had been derived from a c-myc/ras transfection, while no endogenous rat c-myc mRNA was detected in any of the c-jun/ras-or SV40/ras-transformed lines.
Effect of PTA on Focus Formation by c-jun and ras in RECs. c-Ha-ras has been implicated in activating protein kinase C-dependent signal transduction pathways (30) (31) (32) (33) . Also, a ras-responsive element in the polyoma virus enhancer mediating the effects of ras, PTA, and serum has been recently identified and shown to have remarkable similarity to an AP-1/Jun DNA-binding site (34) . Thus, given the comple- (Table 4) . PTA (100 nM) had no visible effect on untransfected RECs and, in addition, did not complement any c-jun expression construct to induce foci of transformed cells. However, we observed that PTA significantly increased the number of ras-and c-jun/ras-induced foci. The effect of PTA on transformation by c-jun/ras resulted in a 3-fold stimulation over transformation by c-jun/ras without PTA and a 10-fold difference over ras alone in the presence of PTA.
DISCUSSION
The structure of v-jun reveals several deletions when compared to c-jun (2) , raising the possibility that the oncogenic activity of v-jun results from mutation. However, our data suggest that the protooncogene c-jun contains the necessary sequences whose deregulated expression in cooperation with 45 *Data for c-jun genomic DNA and cDNA constructs were similar and are pooled. Likewise, similar effects on focus formation were seen with PTA treatment started 2 or 5 days after transfection and the data for both times were pooled.
an activated ras gene can transform RECs and the established Rat-la fibroblast cell line as a single gene. In the Rat-la cells, the level of c-jun mRNA expression appears to correlate with the degree of transformation as seen in morphology, soft agarose colony formation, and nude mouse tumorigenicity. Whether this oncogenic activity of c-jun reflects quantitative or qualitative changes in transcriptional regulation as compared to that of the endogenous rat c-jun gene in nonmalignant cells is presently unknown. Nevertheless, our results indicate that genetic changes in the coding sequence of c-jun are not mandatory for transforming activity, although the mutations seen in v-jun may add to this oncogenic potential.
Data from several laboratories have implicated protein kinase C in the transformation process caused by ras and other oncogenes (30) (31) (32) (33) . Since the tumor-promoting phorbol esters, such as PTA, exert their biologic effects through protein kinase C-dependent signal transduction pathways and act, at least in part, through stimulating transcription of genes with AP-1/Jun DNA-binding sites (3, 19) , we assessed the effect of PTA on transformation by c-jun alone and the combination of c-jun plus ras. While PTA treatment is associated with increased focus formation in ras-transfected cells (35, 36) , our data show that PTA cannot substitute in c-jun-transfected RECs for ras function but potentiates the c-jun/ras combination in transforming RECs. Whether this involves activation of endogenous or exogenous c-jun or other gene(s) is presently unknown. While quantitative and qualitative differences in protein kinase C activation (e.g., through different isoforms of protein kinase C) between ras and PTA might account for some portion of this effect, these results suggest that TPA and ras in this assay system act at least in part on different cellular signal transduction pathways.
p39wjua is a Fos-associated protein which has been shown to be elevated infos-transformed cells (37) . Our experiments have not addressed the role of Fos in transformation by c-jun. Whether a heterodimeric complex formation (38) between Jun and Fos (or Fos-related antigens) as required for the transactivating function of c-jun (5-11) on some heterologous genes or, for example, a competitive interaction with other members of the jun family of genes is required for the transforming activity of c-jun remains to be determined.
